Drugs.com Clinical Trial ResultsOriginal article
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel
Phase 2positivearlocabtagene autoleucelBMS-986393Positive
AI Analysis
Summary
Bristol Myers Squibb announced positive Phase 2 topline results from the registrational QUINTESSENTIAL trial of arlocabtagene autoleucel, a potential first-in-class GPRC5D-directed CAR T cell therapy.
Clinical Trial Data
Outcome Details
Positive topline results from registrational Phase 2 QUINTESSENTIAL trial of GPRC5D-directed CAR T cell therapy
Importance:7/10
Sentiment:
0.85
CAR-ToncologyGPRC5Dfirst-in-classregistrational trial
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 8, 2026 10:09 PM